by Plexium | Apr 28, 2022 | Press Releases
San Diego, California, [April 28, 2022] – Plexium, Inc. (Plexium) and AbbVie (NYSE: ABBV) have entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for neurological conditions. This...
by Plexium | Apr 6, 2022 | Press Releases
San Diego, California, April 6, 2022 – Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced that Plexium President & CEO, Percival Barretto-Ko, will participate at the Longwood Healthcare Leaders Spring MIT...
by Plexium | Feb 23, 2022 | Press Releases
San Diego, California, Feb. 23, 2022 – Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the completion of an oversubscribed $102M financing, led by BVF Partners, L.P. and TCG X, with participation from new...
by Plexium | Feb 3, 2022 | Press Releases
Collaboration Combines Plexium’s Novel Technology Platform With Amgen’s Early Discovery Expertise to Identify and Develop new Therapeutic Agents in Cancer and Other Serious Diseases THOUSAND OAKS and San Diego, Calif. (Feb. 03, 2022) – Amgen (NASDAQ:AMGN) and Plexium,...
by Plexium | Nov 4, 2021 | All Posts, Press Releases
San Diego, Calif., November 4, 2021 – Plexium Inc., (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of experienced biopharmaceutical leader Percival Barretto-Ko as President and Chief Executive Officer...